Baker Bros. Sells 3.1M Celcuity Shares at $102.50, Stake Drops Below 10%
CELC has more than doubled off its 52-week low of $13.47 on elevated volume (2.2× avg).
Summary
Baker Bros. sold 3.1 million Celcuity shares at $102.50 on the day of FDA approval, cutting its stake below 10% and shifting to passive reporting. The sale generated ~$317.8 million but removes an active institutional presence.
Key Events · Ownership and Investor Activity · CELC
-
Baker Bros. Sells 3.1M Shares
On July 14, 2026, Baker Bros. sold 3,100,000 shares at $102.50 per share, generating approximately $317.8 million in proceeds. The sale reduced its beneficial ownership from above 10% to 9.99%.
-
Stake Drops Below 10% Threshold
Post-sale, Baker Bros. holds 4,815,792 common shares (9.99% of outstanding), 6,147,787 prefunded warrants (capped at 9.99% beneficial ownership), and $30.75 million in 2.75% convertible notes (blocked by a 4.99% conversion cap).
-
Switch to Passive Schedule 13G
Baker Bros. stated it is no longer an affiliate and will report on Schedule 13G going forward, indicating a shift from active to passive investment intent.
-
Sale Timed with FDA Approval
The sale occurred on the same day the FDA approved Celcuity's REVTORPYK for advanced breast cancer, suggesting profit-taking after a major catalyst.
Analysis · CELC · Industrial Applications And Services
On July 14, 2026—the very day the FDA approved Celcuity's first drug—Baker Bros. Advisors, a prominent biotech hedge fund, sold 3.1 million shares at $102.50 apiece. The transaction generated roughly $317.8 million in proceeds and trimmed the fund's beneficial ownership from above 10% to exactly 9.99%, prompting a switch from active Schedule 13D to passive Schedule 13G reporting. Selling into the approval pop suggests profit-taking rather than a negative fundamental view, yet the size of the sale and the shift to passive status remove a key institutional backstop. Baker Bros. still retains 4.8 million common shares, 6.1 million prefunded warrants, and $30.75 million in convertible notes, but a 9.99% cap on warrant exercise and a 4.99% blocker on the notes limit near-term conversion. For a newly commercial-stage biotech, this marks a material change in the ownership structure.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CELC was trading at $87.84 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $13.47 to $151.02. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.